LUNG CANCER HARB ORING HER2 MUTATION :EPIDE MIOLOGI CAL CHARACTE RISTICS AND
) U4 `1 a. i2 `' Q* P! DTHERAPE UTIC PERSPECTIVES
6 R* d: T) ?5 R7 D6 h/ ?8 m5 Z! Q8 S* |J. Mazieres, S. Peters
& o+ G+ D* S* j! i7 bIntroduction: HER2 oncogene is a memb er of the EGFR family, encoding atransmembrane receptor that drives and regulates cell proliferation. HER2 mutations are identified in about 2% of non small cell lung cancer (NSCLC) , mainly located in exon 20, and appear to be critical for lung cancer carcinogenesis . Very scarce data are available to define a clinical profile of the patients harboring HER2 mutated NSCLC. We aimed to study clinic opatholog ical characteristics an d therapeutic
# ~6 k. e2 g; A0 w+ youtcomes of patients harboring HER2 mutation in a large European series. Result s:We retrospec tively ide ntified 46 NSCLC patients diagn osed with HER2 exon 20 mut ation. HER2 mutation was mainly exclusive as only one concomitan t KRas mutation was des cribed. Our population was characterized by a median age of 60 yr (31 to 86 yr), a high proportion of women (30 vs. 16 men, 65% ), and of never smokers (24, 52%). All tumors were adenoc arcinomas (two with lepidic features). Half of the patients had stage IV dise ase at the time of diagnosis. HER2 targeted
) a7 i+ l [- F! Ztreatment was delivered after convention al chemothe rapy. A total of 20 anti-Her2' W+ Z* J: S1 I- r. U R' r( o
treatments were eval uable. We observed 4 progressive dise ases, 7 disease stabilizations
1 I, W. t2 d: T& _/ |& @: J& E' ]and 9 partial resp onses according to RECIST 1.1 (overall response rate ORR = 45% ;! ]0 D7 {1 S1 u) }
disease control rate DCR = 80%). Specifica lly, we obse rved a DCR of 92% for0 L! ~4 \& R' J1 T, ~ I4 @6 h* q
trastuzum ab-based therapie s (n = 14), 100 % for afatinib (n = 3) but no response to
0 \/ m7 f+ S9 |) L+ Plapatinib (n = 2) and to a multiTKI (n = 1). Median survival was of 68.2 months and
. y3 o: P2 Z3 e I# g22.9 months for respectively early stage and stag e IV patients.
0 d* r* X7 J1 ?1 ~" S8 x8 d0 RConclusion: This study, the largest to date dedic ated to HER2 mutated NSCLC,: d) ]6 a0 P2 R4 g! i3 P' E
reinforces the importance of an HER2 screening strategy in lung adenoc arcinomas .
+ X; p3 B) I. t: H) r) mHER2-target ed drugs shou ld be tested further, ide ally withi n large collaborative* O {/ d* A0 J4 t8 G" g2 h
clinicaltrials.% U" H/ J% B: `0 A
|